Cumberland Pharmaceuticals Inc. (CPIX), a U.S. specialty pharmaceutical company, has entered into an agreement to transfer its portfolio of branded prescription products to Apotex, a Canadian-based pharmaceutical company, in a transaction valued at $100 million in cash.
The deal will integrate Cumberland's U.S. commercial business into Apotex, creating a broader platform for distributing specialty medicines across the country. The transaction remains subject to authorization and approval by Cumberland's shareholders.
Cumberland will retain its development-stage pipeline, including Ifetroban, a thromboxane antagonist being evaluated across multiple Phase II programs. The company recently reported breakthrough results in a study of Ifetroban for cardiomyopathy associated with Duchenne muscular dystrophy (DMD), and additional trials are underway in systemic sclerosis and idiopathic pulmonary fibrosis (IPF).
CEO A.J. Kazimi said the transaction allows Cumberland to sharpen its focus on advancing these pipeline candidates, while Apotex gains additional commercial scale to support patient care. Apotex CEO Jeff Watson noted that integrating Cumberland's brands will strengthen the company's ability to deliver high-quality medicines across the U.S.
Cumberland will continue to hold its majority ownership in Cumberland Emerging Technologies, which supports early-stage drug development partnerships.
CPIX has traded between $1.85 and $6.27 over the past year. The stock is currently trading at $4.53, up 48.20%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.